Nirmatrelvir-Greasley2022

Introduction to Nirmatrelvir

  • Nirmatrelvir (PF-07321332): A reversible, covalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2.

  • Is the active protease inhibitor in PAXLOVID (combination of nirmatrelvir and ritonavir).

  • Effective against emerging variants of SARS-CoV-2 viruses.

Overview of SARS-CoV-2 Variants

  • Variants of Concern (VOCs) and Variants of Interest (VOIs): Classified by WHO for increased risk to public health.

  • Key VOCs include:

    • Alpha (α, B.1.1.7)

    • Beta (β, B.1.351)

    • Gamma (γ, P.1)

    • Delta (δ, B.1.617.2)

    • Omicron (ο, B.1.1.529)

    • Lambda (λ, B.1.1.1.37/C37)

  • Variants carry mutations affecting Mpro such as:

    • α, β, γ: K90R

    • λ: G15S

    • ο: P132H

In Vitro Studies on Nirmatrelvir

  • Evaluated against the Mpro of prevalent SARS-CoV-2 variants.

  • Found that nirmatrelvir maintains comparative potency against mutant Mpros and wildtype strain (Ki values):

    • Ki for wildtype: 0.933 nM

    • Ki for P132H (Omicron variant): 0.635 nM

    • Notable efficacy in preventing replication of these VOCs/VOIs.

Structural Dynamics and Enzyme Kinetics

  • Molecular basis derived from structural dynamics of nirmatrelvir bound to various Mpros shows no significant changes due to mutations.

  • Mpro Mutant Enzyme Kinetics:

    • K90R: kcat/Km = 28,255 S−1 M−1

    • G15S: kcat/Km = 16,483 S−1 M−1

    • P132H: kcat/Km = 20,800 S−1 M−1

  • Suggests similar catalytic activities compared to wildtype Mpro (kcat/Km = 31,500 S−1 M−1).

Experimental Details

  • Nirmatrelvir potency against mutated Mpro enzymes studied using FRET-based assays.

  • Structural characterization used X-ray crystallography with resolutions between 1.63-Å and 2.09-Å.

Discussion and Implications

  • Nirmatrelvir exhibits sustained antiviral efficacy against major SARS-CoV-2 variants, including Omicron, thus can aid in therapeutics for unvaccinated individuals.

  • Continuous monitoring of emerging variants imperative to evaluate further challenges to antiviral treatments.

  • The findings support the potential of nirmatrelvir as an effective therapeutic option against current and future SARS-CoV-2 variants.